| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10007053 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10007054 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10016656 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10000123 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS20058066 | HPV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS44025335 | HTLV-1 | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KDR |
|---|---|
| DrugBank ID | DB06436 |
| Drug Name | Semaxanib |
| Target ID | BE0000369 |
| UniProt ID | P35968 |
| Regulation Type | |
| PubMed IDs | 16983506; 16736151; 16449240 |
| Citations | Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, Aliff T, Gerald W, Fleisher M, Pfister DG: A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs. 2007 Apr;25(2):165-72. Epub 2006 Sep 16.@@Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A: A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74. Epub 2006 May 31.@@Hoff PM, Wolff RA, Bogaard K, Waldrum S, Abbruzzese JL: A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. Jpn J Clin Oncol. 2006 Feb;36(2):100-3. Epub 2006 Jan 31. |
| Groups | Investigational |
| Direct Classification | Indolines |
| SMILES | CC1=CC(C)=C(N1)C=C1/C(=O)NC2=CC=CC=C12 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL276711 |
